The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Subscribe To Our Newsletter & Stay Updated
